Recommendations for Management of the Trastuzumab (Herceptin) among Iranian Breast Cancer Patients, A Policy Brief
Abstract
Background: Allocation of the new (expensive) drugs for difficult refractory diseases and financial protection of the patients is an important challenge in the national health systems worldwide especially in developing countries. Trastuzumab (Herceptin) as one of the effective but expensive drugs, put major financial burden for the Iranian patients and government. So the Ministry of Health and Medical Education (MOHME), decided to implement a national program for appropriate management of breast cancer and regulation of Trastuzumab in I.R of Iran (NPMBCT). In this policy brief we evaluated this issue and provided necessary recommendations.Method: We designed a conceptual model consisting of the goals, main and supporting processes for management of Trastuzumab in the national program. Five macro-processes selected as the main concerns. Then an expert panel including different scientific disciplines discussed the different aspects of the issue and provided the necessary recommendations. We determined the link between the suggested recommendations and the objectives of the program.Results: Based on the five selected main processes, the experts provided 10 recommendations including: 1) balance in the resource allocation, 2) appropriate modeling for the subsides allocation, 3) avoiding “poor subsidize the rich†phenomenon, 4) development and updating the clinical guidelines, 5) cost-effectiveness analysis on accepted guideline, 6) Quality improvement of diagnostic tests, 7) standardization of the laboratory kits, 8) brand management and lowering the drug cost, 9) improving the patient registry system by ICT infra-structure, 10) development of expert systems to empower the diagnostic laboratories.Conclusion: Given these recommendations, the NPMBCT program will be a successful model for the appropriate management of the expensive drugs and treatment of breast cancer in I.R. of Iran and other developing countries.Mousavi S. Guya M. Ramazani R. Cancer Registra- tion Report for year 2006. Ministry of Health and Medi- cal Education, I.R. of Iran, Tehran; Cancer Office, Center of Non-communicable Disease Control; 2007: 48.
Wolff AC, et al. American Society of Clinical Oncol- ogy/College of American Pathologists guideline recom- mendations for human epidermal growth factor receptor 2 testing in breast cancer. Archives of pathology & labo- ratory medicine 2007; 131(1): 18-43.
Ghaffari SR, et al. Her2 amplification status in Iranian breast cancer patients: comparison of immunohistochem- istry (IHC) and fluorescence in situ hybridisation (FISH). Asian Pacific journal of cancer prevention APJCP 2011; 12(4): 1031-4.
National Comprehensive Cancer Network(NCCN). HER2 Testing: Summary for Breast Cancer Patients. Available from: http://www.nccn.com/about-us/61- symptoms-category.html.
National Institute for Health and Clinical Excellence(NICE). Guidance on the use of Trastuzumab for the treatment of advanced breast cancer. [Cited 2002 March]. Available from: http://publications.nice.org.uk/ guidance-on-the-use-of-Trastuzumab-for-the-treatment- of-advanced-breast-cancer-ta34.
Purmonen TT, et al. Short-course adjuvant Trastuzum- ab therapy in early stage breast cancer in Finland: cost- effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta On- cologica 2011; 50(3): 344-52.
Eniu A, et al. Breast cancer in limited-resource coun- tries: treatment and allocation of resources. The breast journal 2006; 12 Suppl 1: S38-53.
Wagstaff A, Beyond the Herceptin hype…, we need to raise the level of debate. Cancer World, March-April 2006: 14-16.
Wong NS, et al. Management of HER2-positive breast cancer in Asia: consensus statement from the Asian On- cology Summit 2009. The lancet oncology 2009; 10(11): 1077-85.
Guidelines, minimal requirements and standard of cancer care around the Mediterranean Area. Report from 33 www.bccrjournal.com Basic & Clinical Cancer Research, 2014; 6(2): 27-34 the Collaborative AROME (Association of Radiotherapy and Oncology of the Mediterranean Area) working par- ties. Critical reviews in oncology/hematology 2011;8(1): 1-16.
Joensuu H, et al. Adjuvant docetaxel or vinorelbine with or without Trastuzumab for breast cancer. The New England journal of medicine 2006; 354(8): 809-20.
Winkel P. The application of expert systems in the clinical laboratory. Clinical chemistry 1989; 35(8): 1595- 1600.
Valdiguie PM, Role and use of expert systems within the clinical laboratory. Clinica chimica acta; international journal of clinical chemistry 1998; 278(2): 193-202.###
Files | ||
Issue | Vol 6 No 2 (2014) | |
Section | Original Articles | |
Keywords | ||
Trastuzumab Breast Cancer Iran management New High-Cost Cancer Drugs (NHCCD) |
Rights and permissions | |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |